Opko Health (OPK) Cash & Equivalents (2010 - 2026)

Opko Health has reported Cash & Equivalents for 17 years, with the latest figure at $341.9 million in Q1 2026.

• For the quarter ending Q1 2026, Cash & Equivalents fell 21.59% year-over-year to $341.9 million; the trailing twelve-month figure through Mar 2026 stood at $341.9 million (down 21.59% YoY), and the FY2025 full-year result was $369.1 million, down 14.55% from the prior year.
• Cash & Equivalents for Q1 2026 stood at $341.9 million, down from $369.1 million in the prior quarter.
• The five-year high for Cash & Equivalents was $436.0 million in Q1 2025, with the low at $40.6 million in Q2 2024.
• Historically, Cash & Equivalents has averaged $228.7 million across 5 years, with a median of $180.8 million in 2022.
• Annual changes were most pronounced in 2024 — Cash & Equivalents sank 62.47% — and 2025, when it surged 569.65%.
• Opko Health's Cash & Equivalents stood at $153.2 million in 2022, then sank by 37.41% to $95.9 million in 2023, then soared by 350.49% to $431.9 million in 2024, then dropped by 14.55% to $369.1 million in 2025, then dropped by 7.37% to $341.9 million in 2026.
• The last three Cash & Equivalents figures came in at $341.9 million (Q1 2026), $369.1 million (Q4 2025), and $415.2 million (Q3 2025), per Business Quant data.